Pulmatrix (PULM) Non Operating Income (2014 - 2026)
Pulmatrix (PULM) posted Non Operating Income of $120000.0 for Q1 2026, up 700.0% sequentially from -$20000.0 in Q4 2025, and up 207.69% YoY from $39000.0 in Q1 2025.
Pulmatrix (PULM) Non Operating Income (2014 - 2026) Analysis & Trends
Pulmatrix has reported Non Operating Income for 7 years, with the latest figure at $120000.0 in Q1 2026.
- Quarterly Non Operating Income rose 207.69% year-over-year to $120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88000.0 (down 46.67% YoY) and the FY2025 annual result came in at $7000.0, down 96.57% from the prior year.
- Non Operating Income advanced to $120000.0 in Q1 2026 per PULM's latest filing, from -$20000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $175000.0 in Q2 2023 and troughed at -$36000.0 in Q2 2022.
- A 5-year average of $62411.8 and a median of $70000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income slumped 1100.0% in 2022, then soared 1470.0% in 2023.
- Over 5 years, Non Operating Income stood at $109000.0 in 2022, then surged by 30.28% to $142000.0 in 2023, then tumbled by 123.94% to -$34000.0 in 2024, then soared by 41.18% to -$20000.0 in 2025, then jumped by 700.0% to $120000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $120000.0, -$20000.0, and -$11000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | 10,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 175,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Dec 31, 2022 | 109,000.00 |
| Sep 30, 2022 | 48,000.00 |
| Jun 30, 2022 | -36,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 6,000.00 |